UNSPSC 51271624: Butanilicaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C13H19ClN2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 025O9D1EB7, chemically known as o-acetotoluidide, 2-(butylamino)-6-chloro-, monohydrochloride but more generally known as butanilicaine hydrochloride, which bears US NIH Compound Identifier 22378. butanilicaine most often comes in base, dihydrogen phosphate, hydrochloride, and pentafluorobenzamide forms.

Most nations, for tariff and trade purposes, schedule butanilicaine hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, BUTANILICAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Butanilicaine hydrochloride bears US NLM identifiers UMLS ID C0122257 and NCI Concept Code C97303. SMILES: CCCCNCC(=O)NC1C(CCCC1CL)C.CL.

UNSPSC 51271624 Butanilicaine hydrochloride is a Commodity code covering local anesthetic pharmaceutical ingredients and finished pharmaceutical products supplied through state and local cooperative purchasing arrangements. State and local governments procure under this code as part of broader generic pharmaceutical and over-the-counter (OTC) product supply contracts administered through multistate cooperative purchasing alliances; the work involves establishing framework agreements with pharmaceutical manufacturers to supply identified products at negotiated pricing through authorized wholesale distributors to participating public health facilities, hospitals, and other state and local healthcare entities. Issuing bodies soliciting under this code are primarily state procurement offices administering multistate cooperative purchasing vehicles on behalf of multiple participating states and their subordinate local jurisdictions, rather than individual municipalities or counties acting alone.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, with a proposal due date of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating states including Oregon and local government facilities. The RFP requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and evaluates proposals on fixed pricing (10 percent), administrative fee format compliance (5 percent), EDI capability (5 percent), agreement to a 3 percent administrative fee (5 percent), and price competitiveness (75 percent). Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain relationships with at least two of the three authorized wholesalers with chargeback systems, and carry comprehensive insurance including $5 million commercial general liability coverage. The contract term is two years for new vendors with optional extensions, while incumbent vendors' agreements extend through June 30, 2028. No specific dollar values, set-asides, or geographic concentration data are disclosed in the RFP materials.